

## BREAST

FRIDAY APRIL 29, 2022, NOON – 3:00 PM EST

CO-CHAIRS : S.CHIA / E. RAKOVITCH  
SENIOR INVESTIGATORS: L. SHEPHERD / W. PARULEKAR

---

### **CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by Queen's University.*

### **Learning Objectives :**

1. Identify and address, through clinical trial and translational research, the disease burden associated with breast cancer in Canada.
2. Identify clinical trial research opportunities within the Canadian Cancer Trials Group
3. Integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct
4. Apply best practices in clinical trials conduct and analysis to the Canadian Cancer Trials Group research agenda
5. To provide a learning and mentoring environment supportive to new investigators
6. To synthesize, disseminate, exchange and apply knowledge derived from clinical trials to improve the health of Canadians.

---

### **Noon-12:15 pm Welcome and Objectives:**

**S. Chia**

- **Accrual metrics**
- **Recent Publications**
- **CCS Grant Summary**

### **12:15 pm-12:50 pm Closed and screening trials: (5 minutes per trial)**

- **MAC.15** A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer – **S. Dhesy-Thind/S. Chia**
- **MAC.18 POSITIVE:** A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy – **E. Warner**
- **MAC.20** Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer – **P. Goodwin/V. Bernstein**
- **MAC.21** A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial – **M. Salim**
- **MAC.23 RT CHARM:** Phase III Randomized Trial of Hypofractionated Post-Mastectomy Radiation with Breast Reconstruction – **I. Kong**
- **MAC.24** A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with  $\geq 1$  cm Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy – **C. Desbiens**

- **MA.37 PALLAS:** PALbociclib CoLaborative Adjuvant Study A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer – **J. Lemieux**

**12:50 pm–1:30 pm NCTN Current and ongoing trials: (7 minutes per trial)**

- **MAC.19** A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1 -3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy – **S. Latosinsky**
- **MAC.22** Tomosynthesis Mammographic Imaging Screening Trial (TMIST) – **M. Yaffe**
- **MAC.25** A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2 Positive Metastatic Breast Cancer – **S. Chia**
- **MAC.26** A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer – **E. Rakovitch**
- **MAC.27** COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib – **P. Blanchette**
- **MAC.28** Phase III Evaluating De-escalation of Breast Radiation (DEBRA) for Conservative Treatment of Stage 1, HR+, HER2 -, RS <18 Breast Cancer – **V. Theberge**

**1:30 pm-1:45 pm – Break**

**1:45 pm–2:10 pm CCTG-led Current and ongoing trials: (7 minutes per trial)**

- **MA.32** A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer – **P. Goodwin**
- **MA.39** Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer – **T. Whelan**
- **MA.40** A Double-Blind Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced/Metastatic HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER) – **S. Chia**

**2:10 pm–2:30 pm Keynote Presentation**

- **MA.36** A Randomised, Double-Blind, Parallel group, Placebo-Controlled Multicenter Phase III Study to Assess the Efficacy and Safety of Olaparib versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy – **A. Eisen**

**2:30 pm–2:35 pm New Trials Approved and Pending activation:**

- **MA.41** De-Escalation of adjuvant ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 bIockade (DECRESCENDO) – **P. Bedard**

**2:35 pm–2:40 pm IND update – P.Bedard**

- **IND.236** A Phase Ib and Open Label Phase II Study of CFI-402257 in Combination with Weekly Paclitaxel in Patients with Advanced/Metastatic HER2-Negative Breast Cancer
- **IND.237** A Phase II Study of CFI-400945 in Patients with Advanced/Metastatic Breast Cancer
- **IND.239** A Phase II Study of CFI-400945 and Durvalumab in Patients with Advanced/Metastatic Triple Negative Breast Cancer (TNBC)
- **IND.241** A Phase II Study of V800 with Nivolumab

**2:40 pm–2:55 pm New Proposals**

- PrE0114/AMMBER – **D. Cescon**
- De-escalation of adjuvant pembrolizumab post neoadjuvant treatment in pCR – **S. Chia**

**2:55 pm–3:00 pm Marathon of Hope and Confluence – S. Chia**

**3:00 pm Adjournment**



**Breast Disease Site Executive Committee members**

<b>Name</b>	<b>Trial/ Committee</b>	<b>Role</b>
Dr. Valerie Theberge	DSCBRE	EXEC
Dr. Julie Lemieux	DSCBRE	LIAS
Dr. Jean-Francois Boileau	DSCBRE	EXEC
Dr. Eileen Rakovitch	DSCBRE	EXEC
Dr. Philippe Bedard	DSCBRE	EXEC
Dr. Nicholas Meti	DSCBRE	EXEC
Dr. Danielle Rodin	DSCBRE	LIAS
Dr. Bingshu E. Chen	DSCBRE	EXEC
Ms. Cathy Davidson	DSCBRE	LIAS
Ms. Amy Hawkins	DSCBRE	LIAS
Dr. Wendy Parulekar	DSCBRE	EXEC
Dr. Lois Shepherd	DSCBRE	EXEC
Dr. Muriel Brackstone	DSCBRE	EXEC
Dr. Lisa Barbera	DSCBRE	LIAS
Dr. Brandon Bernard	DSCBRE	EXEC
Dr. Stephen Chia	DSCBRE	EXEC
Ms. Wendy Won	DSCBRE	LIAS
Ms. Rosanne Serpanchy	DSCBRE	LIAS
Dr. Peter H. Watson	DSCBRE	EXEC
Ms. Sylvie A. Desmarais	DSCBRE	LIAS
Ms. Martina Wood	DSCBRE	EXEC

Recent Publications:

MAC4/MAC5 - Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials *The Lancet Oncology* Volume 23, ISSUE 3, P382-392, March 01, 2022

MAC14 - Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108) *J Clin Oncol* 2022.

MA37 - Treatment Exposure and Discontinuation in the PALbociclib CoLLaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03) *J Clin Oncol* 2022.

MAC9 - Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). *Supportive Care in Cancer* 29: 2509-17, 2021.

MAC12 - Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy (ONLINE). *Cancer* n/a: 2021.

MA37 - Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) (ONLINE). *J Clin Oncol JCO*, 2021.

MA17R - Predicting the clinical outcomes and benefit from letrozole after 5-áyears of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R (ONLINE). *Breast Cancer Res Treat* 2021.

MA5 and MA12 - Predictive significance of an optimized panel for basal-like breast cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 phase III clinical trials (ONLINE). *Clin Cancer Res* 2021.

MA32- Effect of metformin versus placebo on metabolic factors in the MA32 randomized breast cancer trial *Breast Cancer* 7: 74, 2021.

MA32 - The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group JNCI: *Journal of the National Cancer Institute* 113: 192-8, 2021.

STAGE_TYPE	ENROLLMENT				
	Count of ID	2020	2021	2022	Grand Total
CAKK-Kingston Health Sciences Centre	9	2			11
CAKO-Ottawa Hospital Research Institute	12	13	1		26
CAMP-University Health Network Princess Margaret Cancer Centre	29	32	4		65
CAVA-BCCA - Vancouver Cancer Centre	5	17	6		28
CAMN-Odette Cancer Centre Sunnybrook Health Sciences Centre	9	12	2		23
CANI-London Regional Cancer Program	14	4	2		20
CASA-Allan Blair Cancer Centre	7	2	3		12
CAAJ-Dr. H. Bliss Murphy Cancer Centre	2	1			3
CABN-QEII Health Sciences Centre Capital District Health Authority	2	3			5
CAEJ-Regional Health Authority B, Zone 2 Saint John Regional Hospital	12	6			18
CAGB-Hopital de la Cite-de-la-Sante	2	2			4
CAGH-CIUSSS de l'Estrie - Centre hospitalier universitaire de Sherbrooke	4	4			8
CAGQ-Hotel-Dieu de Quebec	20	17	1		38
CAHA-CIUSSS de l'Est-de-l'Île-de-Montreal Hopital Maisonneuve-Rosemont	2	3	1		6
CAH-The Jewish General Hospital	11	12	1		24
CAHN-CHUM-Centre Hospitalier de l'Universite de Montreal	3	13			16
CAHO-Centre Integre de Sante et de Services Sociaux de la Monteregie-Centre	3	14	3		20
CAHU-The Research Institute of the McGill University Health Centre	3	4	1		8
CALC-Niagara Health System	5	5			10
CALM-Juravinski Cancer Centre at Hamilton Health Sciences	15	13	4		32
CAMR-Royal Victoria Regional Health Centre	9	14	5		28
CAMU-Trillium Health Partners - Credit Valley Hospital	2	2			4
CANG-Grand River Regional Cancer Centre at Grand River Hospital	11	6			17
CAPN-Health Sciences North	3	3			6
CAPS-Algoma District Cancer Program Sault Area Hospital	3	3			6
CARM-CancerCare Manitoba	10	1			11
CATC-Tom Baker Cancer Centre	22	22	5		49
CATW-Cross Cancer Institute	13	20	2		35
CAVF-BCCA - Fraser Valley Cancer Centre	6	4	3		13
CAVK-BCCA - Cancer Centre for the Southern Interior	10	15	1		26
CAVO-BCCA - Abbotsford Centre	1	1			2
CAVR-BCCA - Centre for the North	1	10	2		13
CAVV-BCCA - Vancouver Island Cancer Centre	15	14	3		32
USXU-University of Southern California	2	2			4
USXU-Cancer Trials Support Unit	30	63	23		116
USXU-Poudre Valley Hospital	1	1			2
USXU-PENROSE CANCER CENTER, COLO. SPRINGS, COLORADO	2	2			4
USXU-Memorial Hospital Colorado Springs	2	1			3
USXU-University of Colorado Cancer Center	1	1			2
USXU-MEMORIAL REGIONAL HOSPITAL HOLLYWOOD, FL	1	1			2
USXU-University of Miami, Miami, Florida	1	1			2
USXU-Boca Raton Regional Hospital	2	2			4
USXU-Moffitt Cancer Center and Research Institute	1	9	1		11
USXU-Mayo Clinic in Florida	2	2			4
USXU-Morton Plant Hospital	1	4	2		7
USXU-Rush University Medical Center	1	1			2
USXU-Decatur Memorial Hospital	1	1			2
USXU-Carle Cancer Center CCOP	1	1			2
USXU-Indiana University Medical Center	3	3			6
USXU-Via Christi Regional Medical Center	1	1			2
USXU-University of Louisville	1	1			2
USXU-Baystate Medical Center	2	2			4
USXU-Beth Israel Deaconess Medical Center	2	2			4
USXU-Lowell General Hospital	2	1			3
USXU-Greater Baltimore Medical Center	2	3			5
USXU-William Beaumont Hospital	2	2			4
USXU-Providence Hospital	1	1			2
USXU-University of Michigan	3	3			6
USXU-Saint Mary's Health Care (Member of Grand Rapids Clinical Oncology Program -GRCOP)	1	1			2
USXU-GRCOP/ Munson Medical	2	1			3
USXU-Metro Health (Member of Grand Rapids Clinical Oncology Program)	1	1			2
USXU-Altru Cancer Center	1	2	1		4
USXU-Dartmouth-Hitchcock Medical Center	1	1			2
USXU-New Hampshire Oncology Hematology Associates	2	2			4
USXU-Beth Israel Medical Center - CCC West Side Campus	6	6			12
USXU-New York University Langone Medical Center	1	2			3
USXU-Columbia University Medical Center	1	1	1		3
USXU-Rochester General Hospital	1	1			2
USXU-Stony Brook University Medical Center Cancer Center	2	4	1		7
USXU-Ohio State University The James Comprehensive Breast Center	1	4	1		6
USXU-Akron General Medical Center	1	1			2
USXU-Aultman Hospital	1	1			2
USXU-Women Infants Hospital of Rhode Island	1	1			2
USXU-Medical University of South Carolina, Hollings Cancer Center	5	1			6
USXU-Cancer Therapy & Research Center @ Univ. of Texas Health Sciences Center	1	1			2
USXU-Huntsman Cancer Institute	1	1	3		5
USXU-Marshfield Clinic-Minocqua Center	1	1			2
USXU-University of Wisconsin Pharmaceutical Research Center	3	6	1		10
USXU-Wausau Hospital Center	1	1			2
USXU-Gundersen Lutheran Health System CCOP	1	1			2
USXU-West Virginia University, Department of Medicine - Hematology/Oncology	1	1			2
CAGS-CHA-Hopital Du St-Sacrement	1	7	1		9
CALP-William Osler Health System Brampton City Hospital	1	1			2
CALY-Stronach Regional Health Centre at Southlake	10	6	1		17
CANW-Windsor Regional Cancer Centre	3	3			6
CAEM-The Moncton Hospital	6	6			12
CAMT-North York General Hospital	1	1			2
CANE-Cambridge Memorial Hospital	7	7			14
CAER-The Vitalite Health Network - Dr. Leon Richard Oncology Centre	9	9			18
CASS-Saskatoon Cancer Centre	14	2			16
CAJN-Centre integre de sante et de services sociaux de L'Outaouais (CISSSO)	2	1			3
CAHF-Centre Integre Universitaire De Sante Et De Services CIUSSS NIM - Hopital du sacre-coeur de Montreal	2	1			3
CAMH-Humber River Hospital	4	3			7
<b>Grand Total</b>	<b>369</b>	<b>460</b>	<b>105</b>		<b>934</b>

